Other safety alerts
|
| |
| Australia: Solgar ABC Dophilus powder may pose a serious risk to health |
| |
The Therapeutic Goods Administration (TGA) announced that certain batches of Solgar ABC Dophilus powder may pose a serious risk to your health, or the health of your child, and should not be taken.
TGA has received advice from the United States Food and Drug Administration (USFDA) that testing of lot numbers 074024-01R1, 074024-01, 074024-02 Expiration Date 7/31/15 conducted by the Center for Disease Control of a product labelled Solgar ABC Dophilus powder found that those batches contain the presence of Rhizopus oryzae in 1.75 oz (50 g) containers. Rhizopus oryzae can cause Mucormycosis, which is a rare infection that may cause health problems, particularly in pre-mature infants/infants and children.
Please refer to the following website in TGA for details:
http://www.tga.gov.au/alert/solgar-abc-dophilus-powder
In Hong Kong, the above product is not a registered pharmaceutical product. Related news has been released by United States Food and Drug Administration and was posted on the Drug Office website on 18 November 2014.
Ends/ Saturday, November 29, 2014
Issued at HKT 12:00
|
| |
|
